T. Rowe Price Associates’s Verastem VSTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$249K Buy
46,827
+19,591
+72% +$121K ﹤0.01% 2760
2025
Q4
$211K Sell
27,236
-550,796
-95% -$4.91M ﹤0.01% 2788
2025
Q3
$5.11M Buy
578,032
+555,377
+2,451% +$4.13M ﹤0.01% 1383
2025
Q2
$95K Buy
22,655
+4,603
+25% +$28.8K ﹤0.01% 2904
2025
Q1
$109K Buy
18,052
+2,662
+17% +$16.3K ﹤0.01% 2804
2024
Q4
$80K Buy
15,390
+129
+0.8% +$508 ﹤0.01% 2877
2024
Q3
$46K Buy
+15,261
New +$41.4K ﹤0.01% 2939
2022
Q2
Sell
-1,260
Closed -$21K 3017
2022
Q1
$21K Buy
1,260
+308
+32% +$5.3K ﹤0.01% 2957
2021
Q4
$23K Sell
952
-241
-20% -$7.61K ﹤0.01% 2956
2021
Q3
$44K Buy
1,193
+41
+4% +$1.51K ﹤0.01% 2909
2021
Q2
$56K Buy
1,152
+168
+17% +$7K ﹤0.01% 2893
2021
Q1
$29K Buy
984
+2
+0.2% +$56 ﹤0.01% 2836
2020
Q4
$25K Hold
982
﹤0.01% 2659
2020
Q3
$14K Sell
982
-86,700
-99% -$1.43M ﹤0.01% 2588
2020
Q2
$1.81M Buy
+87,682
New +$2.32M ﹤0.01% 1560
2020
Q1
Sell
-27,450
Closed -$441K 2564
2019
Q4
$441K Buy
27,450
+5,925
+28% +$85.2K ﹤0.01% 2192
2019
Q3
$313K Hold
21,525
﹤0.01% 2267
2019
Q2
$390K Buy
21,525
+17,731
+467% +$402K ﹤0.01% 2212
2019
Q1
$135K Buy
3,794
+17
+0.5% +$672 ﹤0.01% 2445
2018
Q4
$152K Buy
3,777
+9
+0.2% +$549 ﹤0.01% 2450
2018
Q3
$328K Buy
3,768
+1,102
+41% +$110K ﹤0.01% 2327
2018
Q2
$220K Sell
2,666
-1,276
-32% -$78.1K ﹤0.01% 2433
2018
Q1
$141K Sell
3,942
-5,108
-56% -$198K ﹤0.01% 2461
2017
Q4
$333K Buy
+9,050
New +$409K ﹤0.01% 2243

Other funds holding VSTM

T. Rowe Price Associates's VSTM Position: Q1 2026 in Review

T. Rowe Price Associates increased its Verastem (VSTM) stake by 72% in Q1 2026, buying an estimated $121K and bringing the position to 46,827 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

T. Rowe Price Associates first reported a position in VSTM in Q4 2017 and has held it in 24 quarters since. The position peaked at $5.11M in Q3 2025. 155 funds tracked by Wall St. Rank hold VSTM as of Q1 2026.

  • T. Rowe Price Associates held 46,827 shares of Verastem worth $249K as of Q1 2026.
  • T. Rowe Price Associates bought 19,591 Verastem shares in Q1 2026, an estimated $121K.
  • Verastem made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2760 holding.
  • T. Rowe Price Associates first reported a position in Verastem in Q4 2017 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Verastem position peaked at $5.11M in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Verastem as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.